Clinical trials: Smouldering Myeloma, active
Smouldering Myeloma
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.
- Trial name
- MODIFY (NCT06762769)
- Testing
- Isatuximab, Iberdomide, Dexamethasone
- Where
- 14 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
Smouldering Myeloma
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
Randomized (2:1) multi-center open-label phase II trial. Patients with high-risk SMM will be enrolled on the study and treated with KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg…
- Trial name
- HO147SMM (NCT03673826)
- Testing
- Carfilzomib, Dexamethasone, Lenalidomide
- Where
- 16 sites in Czechia, Italy and 2 more
- Volunteers
- 58 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland